Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 28, 2026, titled "Glenmark Pharmaceuticals Inc., USA launches Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials".
